학술논문
The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment
Document Type
Article
Author
Source
In: Kidney International . (Kidney International, July 2021, 100(1):225-237)
Subject
Language
English
ISSN
15231755
00852538
00852538